FMI
RXST icon

F/M Investments’s RxSight RXST Stock Holding History

F/M Investments’s Portfolio RXST Stock Details RXST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,901
Closed -$203K – 407
2024
Q4 		$203K Buy
5,901
+659
+13% +$29.7K 0.01% 394
2024
Q3 		$259K Sell
5,242
-30
-0.6% -$1.54K 0.01% 319
2024
Q2 		$317K Buy
+5,272
New +$301K 0.01% 297

Other funds holding RXST

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DSCM
Divisadero Street Capital Management Miami, Florida $2.39B AUM 134.55% 1-Year Est. Return

F/M Investments's RXST Position: Q1 2025 in Review

F/M Investments sold out of RxSight (RXST) in Q1 2025, closing a stake of 5,901 shares — an estimated $203K sold.

F/M Investments first reported a position in RXST in Q2 2024 and held it in 3 quarters. The position peaked at $317K in Q2 2024. 192 funds tracked by Wall St. Rank hold RXST as of Q1 2025.

  • F/M Investments reported no remaining RxSight position as of Q1 2025 after selling out during the quarter.
  • F/M Investments sold 5,901 RxSight shares in Q1 2025, an estimated $203K.
  • F/M Investments first reported a position in RxSight in Q2 2024 and held it in 3 quarters.
  • F/M Investments's RxSight position peaked at $317K in Q2 2024.
  • 192 funds tracked by Wall St. Rank held RxSight as of Q1 2025.

Based on F/M Investments's 13F filing for Q1 2025, filed 14 May 2025.